This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-07. Anything still debated is marked as such rather than presented as settled.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Most industries are located in the industrial-port area north of the estuary and east of the city of Le Havre. The largest industrial employer (2,400 employees) of the Le Havre region is the Renault public company in the commune of Sandouville. The second important sector for the industrial zone is petrochemicals. The Le Havre region has more than a third of French refining capacity. It provides about 50% of the production of basic plastics and 80% of additives and oils with more than 3,500 researchers working in private and public laboratories. Large firms in the chemical industry are mainly in the communes of Le Havre (Millenium Chemicals Le Havre), Montivilliers (TotalEnergies, Yara, Chevron Oronite SA, Lanxess, etc.) and Sandouville (Goodyear Chemicals Europe). A total of 28 industrial establishments manufacture plastics in the Le Havre area many of which are classed as SECESO. There are several firms in the aerospace industry: SAFRAN Nacelles, a supplier to Airbus, Boeing and other commercial air-framers, making jet engine nacelles and thrust reversers, is located in Harfleur and employs 1,200 people from the Le Havre area. Finally, Dresser-Rand SA manufactures equipment for the oil and gas industry and employs about 700 people. In the energy field, the EDF thermal power plant of Le Havre has an installed capacity of 1,450MW and operates using coal with 357 employees. The AREVA group announced the opening of a factory for building wind turbines: installed in the port of Le Havre, it should create some 1,800 jobs.
Alternative splicing of intron 9 creates the β and γ isoforms with altered C-termini. An internal promoter in intron 4 produces the ∆133 and ∆160 isoforms, which lack part of the TAD and DBD. Alternative translation initiation at codons 40 or 160 results in ∆40p53 and ∆160p53 isoforms, respectively.
In the run-up to the Second World War Tolkien was earmarked as a codebreaker. In January 1939 he was asked to serve in the cryptographic department of the Foreign Office in the event of national emergency. Beginning on 27 March, he took an instructional course at the London headquarters of the Government Code and Cypher School. He was informed in October that his services would not be required. In 1945 Tolkien moved to Merton College, Oxford, becoming the Merton Professor of English Language and Literature, in which post he remained until his retirement in 1959. He served as an external examiner for University College, Galway (now the University of Galway), for many years. In 1954 Tolkien received an honorary doctorate from the National University of Ireland (of which University College, Galway, was a constituent college). Tolkien completed The Lord of the Rings in 1948, close to a decade after the first sketches.
Australia has 43 universities, with 37 being public universities. The Group of Eight includes some of the oldest public universities in Australia, including the University of Queensland, University of Sydney, University of Melbourne, University of New South Wales, University of Adelaide, University of Western Australia, Australian National University, and Monash University. The Australian Technology Network of public universities grew from the former Institutes of Technology and include RMIT University, Queensland University of Technology, Curtin University, the University of Technology Sydney, and the University of South Australia. These former technology institutes gained university status in the late 1980s through the early 1990s due to the reforms made by John Dawkins, then Minister for Employment, Education, and Training. Innovative Research Universities represents several public research-intensive institutions, with most members being established in the 1960s and 1970s. The group includes Charles Darwin University, James Cook University, Griffith University, La Trobe University, Flinders University, Murdoch University, and Western Sydney University. The Regional Universities Network includes seven regional Australian public universities, including Central Queensland University, Southern Cross University, Federation University, the University of Southern Queensland, the University of the Sunshine Coast, University of New England (Australia), and Charles Sturt University.
In 1968, the CCP supported a new system of health care delivery for rural areas. Villages were assigned a barefoot doctor (a medical staff with basic medical skills and knowledge to deal with minor illnesses) responsible for basic medical care. The medical staff combined the values of traditional China with modern methods to provide health and medical care to poor farmers in remote rural areas. The barefoot doctors became a symbol of the Cultural Revolution, for the introduction of modern medicine into villages where traditional Chinese medicine services were used. The barefoot doctor system represents a hybrid of modern and traditional Chinese medicine (Chinese: 中西医结合; lit. 'Chinese western medicine combination', usually translated "Integrative Chinese Medicine"), a guiding principle that has far outlived the barefoot doctor system. Nathan Sivin's 1987 translation of Revised Outline of Chinese Medicine: For Western-medicine practitioners to learn Chinese medicine (新编中医学概要：供西医学习中医用; 1972) serves as a good, though outdated, example of this principle in practice. The State Intellectual Property Office (now known as CNIPA) established a database of patents granted for traditional Chinese medicine. In the second decade of the twenty-first century, Chinese Communist Party general secretary Xi Jinping strongly supported TCM, calling it a "gem". As of May 2011, in order to promote TCM worldwide, China had signed TCM partnership agreements with over 70 countries.
Sources: en.wikipedia.org
== Methods == One-place studies exploit manuscript ecclesiastical and civil records to explore the microhistory of the villagers and their lives. In Europe, such records usually date back to about 1600 and include:
Iron typically damages cells in the heart, liver and elsewhere, causing adverse effects that include coma, metabolic acidosis, shock, liver failure, coagulopathy, long-term organ damage, and even death. Humans experience iron toxicity when the iron exceeds 20 milligrams for every kilogram of body mass; 60 milligrams per kilogram is considered a lethal dose. Overconsumption of iron, often the result of children eating large quantities of ferrous sulfate tablets intended for adult consumption, is one of the most common toxicological causes of death in children under six. The Dietary Reference Intake (DRI) sets the Tolerable Upper Intake Level (UL) for adults at 45 mg/day. For children under fourteen years old the UL is 40 mg/day. The medical management of iron toxicity is complicated, and can include use of a specific chelating agent called deferoxamine to bind and expel excess iron from the body.
=== On bone formation === Due to myostatin's ability to inhibit muscle growth, it can indirectly inhibit bone formation by decreasing the load on the bone. It has a direct signalling effect on bone formation as well as degradation. Knockdown of myostatin has been shown to reduce formation of osteoclasts (multinucleated cells responsible for the breakdown of bone tissue) in mice modeling rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disorder that, among other effects, leads to the degradation of the bone tissue in affected joints. Myostatin has not, however, been shown to be solely sufficient for the formation of mature osteoclasts from macrophages, only an enhancer. Myostatin expression is increased around the site of a fracture. Suppression of myostatin at the fracture site leads to increased callus and overall bone size, further supporting the inhibitory effect of myostatin on bone formation. One study by Berno Dankbar et al., 2015 found that myostatin deficiency leads to a notable reduction in inflammation around a fracture site. Myostatin affects osteoclastogenesis by binding to receptors on osteoclastic macrophages and causing a signalling cascade. The downstream signalling cascade enhances the expression of RANKL-dependent integrin αvβ3, DC-STAMP, calcitonin receptors, and NFATc1 (which is part of the initial intracellular complex that starts the signaling cascade, along with R-Smad2 and ALK4 or ALK5).
Xylem tissue is organised in a tube-like fashion along the main axes of stems and roots. It consists of a combination of parenchyma cells, fibers, vessels, tracheids, and ray cells. Longer tubes made up of individual cells are vessels, while vessel members are open at each end. Internally, there may be bars of wall material extending across the open space. These cells are joined end-to-end to form long tubes. Vessel members and tracheids are dead at maturity. Tracheids have thick secondary cell walls and are tapered at the ends. They do not have end openings such as the vessels. The end overlap with each other, with pairs of pits present. The pit pairs allow water to pass from cell to cell. Though most conduction in xylem tissue is vertical, lateral conduction along the diameter of a stem is facilitated via rays. Rays are horizontal rows of long-living parenchyma cells that arise out of the vascular cambium.
A 2015 US study of the stated preferences of 75 women using 3D-printed models as references showed a preferred penis length of 16 cm (6.3 in) and a preferred circumference of 12.2 cm (4.8 in) for long-term sexual partners, with slightly larger preferred sizes of a length of 16.3 cm (6.4 in) and circumference of 12.7 cm (5.0 in) for one-time sexual encounters. Many studies measure length "bone pressed" where the pubic fat pad is compressed to give a larger measurement, but due to the methods the above numbers are effectively non "bone pressed". This difference in measurement method was found to be on average 1.8 cm (0.7 in) . So preferred length of long term and one time partners was 17.8 cm (7.0 in)and 18.1 cm (7.1 in) respectively.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.